Showing results (101-110 of 163) with videos related to

Sort By:
Pageof 17
Haematologica|July 10, 2025
The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemiaHelong Gary Zhao, Nataly Cruz-Rodriguez, Kent C Johnson, et al.
Cancer Research|July 27, 2013
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitorsAmie S Corbin, Thomas O'Hare, Zhimin Gu, et al.
The New England Journal of Medicine|March 9, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaAndreas Hochhaus, Richard A Larson, François Guilhot, et al.
Cell Reports|March 30, 2017
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid LeukemiaAlyssa Carey, David K Edwards, Christopher A Eide, et al.
British Journal of Haematology|January 4, 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaMichael W Deininger, Kenneth J Kopecky, Jerald P Radich, et al.
Hematological Oncology|April 24, 2019
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasmsTariq I Mughal, Naveen Pemmaraju, Jerald P Radich, et al.
Cancers|October 13, 2021
Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in MyelofibrosisSimone Claudiani, Clinton C Mason, Dragana Milojkovic, et al.
Molecular and Cellular Biology|August 2, 2006
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinibIan J Griswold, Mary MacPartlin, Thomas Bumm, et al.
Blood Advances|May 31, 2022
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosisAndreas Reiter, Juliana Schwaab, Daniel J DeAngelo, et al.
Leukemia|July 21, 2018
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMMLSandrine Niyongere, Nolwenn Lucas, Jun-Min Zhou, et al.
Pageof 17